| Interactions between Microbiome and DME (MICBIO)
|
| Bacteria: Actinobacteria |
|---|
| Bifidobacterium adolescentis (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 5 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium adolescentis co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium adolescentis co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium adolescentis co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium adolescentis co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium adolescentis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Bifidobacterium animalis (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium animalis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [6], [7] |
| Bifidobacterium breve (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium breve co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium breve co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium breve co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium breve co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium breve co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium breve co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Bifidobacterium dentium (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium dentium co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [9] |
| Bifidobacterium longum (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 5 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium longum co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium longum co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium longum co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium longum co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium longum co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Bifidobacterium ruminatum (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 8 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium ruminatum co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Dasatinib |
Click to Show/Hide the Detail |
| Drug ID |
DR0423
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium ruminatum co-metabolize the drug Dasatinib, which can collectively affect efficacy, safety or bioavailability of this drug. |
[10], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium ruminatum co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Losartan potassium |
Click to Show/Hide the Detail |
| Drug ID |
DR0984
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium ruminatum co-metabolize the drug Losartan potassium, which can collectively affect efficacy, safety or bioavailability of this drug. |
[11], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium ruminatum co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium ruminatum co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Oxybutynin chloride |
Click to Show/Hide the Detail |
| Drug ID |
DR1219
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium ruminatum co-metabolize the drug Oxybutynin chloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[12], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bifidobacterium ruminatum co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Collinsella intestinalis (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Collinsella intestinalis co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Collinsella intestinalis co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Collinsella intestinalis co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Collinsella intestinalis co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Collinsella intestinalis co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Collinsella intestinalis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Corynebacterium amycolatum (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Corynebacterium amycolatum co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [14] |
| Corynebacterium jeikeium (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Corynebacterium jeikeium co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [14] |
| Eggerthella lenta (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eggerthella lenta co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eggerthella lenta co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eggerthella lenta co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paclitaxel |
Click to Show/Hide the Detail |
| Drug ID |
DR1227
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eggerthella lenta co-metabolize the drug Paclitaxel, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eggerthella lenta co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eggerthella lenta co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Mycobacterium tuberculosis (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Dextromethorphan hydrobromide |
Click to Show/Hide the Detail |
| Drug ID |
DR0476
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Mycobacterium tuberculosis co-metabolize the drug Dextromethorphan hydrobromide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[11], [15] |
| Streptomyces avermitilis (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Testosterone cypionate |
Click to Show/Hide the Detail |
| Drug ID |
DR1564
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Streptomyces avermitilis co-metabolize the drug Testosterone cypionate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[16], [17], [18] |
| Streptomyces griseus (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Doxorubicin |
Click to Show/Hide the Detail |
| Drug ID |
DR0546
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Streptomyces griseus co-metabolize the drug Doxorubicin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[19], [20] |
| Bacteria: Bacteroidetes |
|---|
| Alistipes indistinctus (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 10 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Alistipes indistinctus co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Diltiazem hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0509
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Alistipes indistinctus co-metabolize the drug Diltiazem hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[21], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Alistipes indistinctus co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Alistipes indistinctus co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Alistipes indistinctus co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Alistipes indistinctus co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Alistipes indistinctus co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Alistipes indistinctus co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Alistipes indistinctus co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Alistipes indistinctus co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Bacteroides caccae (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 5 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides caccae co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides caccae co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides caccae co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides caccae co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides caccae co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Bacteroides cellulosilyticus (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 4 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides cellulosilyticus co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides cellulosilyticus co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides cellulosilyticus co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides cellulosilyticus co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Bacteroides coprophilus (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 5 Drugs Metabolized
|
| Clonidine |
Click to Show/Hide the Detail |
| Drug ID |
DR0352
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides coprophilus co-metabolize the drug Clonidine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[23], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides coprophilus co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides coprophilus co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides coprophilus co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides coprophilus co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Bacteroides dorei (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 17 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clonidine |
Click to Show/Hide the Detail |
| Drug ID |
DR0352
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Clonidine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[23], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Dexamethasone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR0451
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Dexamethasone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[25], [1] |
| Diltiazem hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0509
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Diltiazem hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[21], [1] |
| Finasteride |
Click to Show/Hide the Detail |
| Drug ID |
DR0695
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Finasteride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Losartan potassium |
Click to Show/Hide the Detail |
| Drug ID |
DR0984
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Losartan potassium, which can collectively affect efficacy, safety or bioavailability of this drug. |
[11], [1] |
| Mifepristone |
Click to Show/Hide the Detail |
| Drug ID |
DR1091
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Mifepristone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[26], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Oxybutynin chloride |
Click to Show/Hide the Detail |
| Drug ID |
DR1219
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Oxybutynin chloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[12], [1] |
| Phenytoin |
Click to Show/Hide the Detail |
| Drug ID |
DR1282
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Phenytoin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[27], [1] |
| Ritonavir |
Click to Show/Hide the Detail |
| Drug ID |
DR1430
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Ritonavir, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Zaleplon |
Click to Show/Hide the Detail |
| Drug ID |
DR1725
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides dorei co-metabolize the drug Zaleplon, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Bacteroides eggerthii (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 10 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides eggerthii co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides eggerthii co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides eggerthii co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides eggerthii co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Nateglinide |
Click to Show/Hide the Detail |
| Drug ID |
DR1132
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides eggerthii co-metabolize the drug Nateglinide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides eggerthii co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides eggerthii co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Ritonavir |
Click to Show/Hide the Detail |
| Drug ID |
DR1430
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides eggerthii co-metabolize the drug Ritonavir, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides eggerthii co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides eggerthii co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Bacteroides finegoldii (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 4 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides finegoldii co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides finegoldii co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides finegoldii co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides finegoldii co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Bacteroides fragilis (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 23 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clonidine |
Click to Show/Hide the Detail |
| Drug ID |
DR0352
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Clonidine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[23], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Dasatinib |
Click to Show/Hide the Detail |
| Drug ID |
DR0423
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Dasatinib, which can collectively affect efficacy, safety or bioavailability of this drug. |
[10], [1] |
| Dexamethasone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR0451
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Dexamethasone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[25], [1] |
| Finasteride |
Click to Show/Hide the Detail |
| Drug ID |
DR0695
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Finasteride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Losartan potassium |
Click to Show/Hide the Detail |
| Drug ID |
DR0984
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Losartan potassium, which can collectively affect efficacy, safety or bioavailability of this drug. |
[11], [1] |
| Metronidazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1073
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Metronidazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[28], [29], [30] |
| Mifepristone |
Click to Show/Hide the Detail |
| Drug ID |
DR1091
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Mifepristone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[26], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Nateglinide |
Click to Show/Hide the Detail |
| Drug ID |
DR1132
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Nateglinide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Oxybutynin chloride |
Click to Show/Hide the Detail |
| Drug ID |
DR1219
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Oxybutynin chloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[12], [1] |
| Paclitaxel |
Click to Show/Hide the Detail |
| Drug ID |
DR1227
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Paclitaxel, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Ritonavir |
Click to Show/Hide the Detail |
| Drug ID |
DR1430
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Ritonavir, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Tadalafil |
Click to Show/Hide the Detail |
| Drug ID |
DR1525
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Tadalafil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[31], [1] |
| Zaleplon |
Click to Show/Hide the Detail |
| Drug ID |
DR1725
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides fragilis co-metabolize the drug Zaleplon, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Bacteroides intestinalis (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides intestinalis co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides intestinalis co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides intestinalis co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides intestinalis co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides intestinalis co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides intestinalis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Bacteroides oleiciplenus (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides oleiciplenus co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [32] |
| Bacteroides ovatus (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 7 Drugs Metabolized
|
| Clonidine |
Click to Show/Hide the Detail |
| Drug ID |
DR0352
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides ovatus co-metabolize the drug Clonidine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[23], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides ovatus co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Diltiazem hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0509
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides ovatus co-metabolize the drug Diltiazem hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[21], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides ovatus co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides ovatus co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides ovatus co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides ovatus co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Bacteroides sartorii (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 19 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clonidine |
Click to Show/Hide the Detail |
| Drug ID |
DR0352
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Clonidine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[23], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Dexamethasone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR0451
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Dexamethasone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[25], [1] |
| Diltiazem hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0509
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Diltiazem hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[21], [1] |
| Finasteride |
Click to Show/Hide the Detail |
| Drug ID |
DR0695
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Finasteride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Losartan potassium |
Click to Show/Hide the Detail |
| Drug ID |
DR0984
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Losartan potassium, which can collectively affect efficacy, safety or bioavailability of this drug. |
[11], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Nateglinide |
Click to Show/Hide the Detail |
| Drug ID |
DR1132
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Nateglinide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Oxybutynin chloride |
Click to Show/Hide the Detail |
| Drug ID |
DR1219
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Oxybutynin chloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[12], [1] |
| Paclitaxel |
Click to Show/Hide the Detail |
| Drug ID |
DR1227
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Paclitaxel, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Phenytoin |
Click to Show/Hide the Detail |
| Drug ID |
DR1282
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Phenytoin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[27], [1] |
| Ritonavir |
Click to Show/Hide the Detail |
| Drug ID |
DR1430
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Ritonavir, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Zaleplon |
Click to Show/Hide the Detail |
| Drug ID |
DR1725
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides sartorii co-metabolize the drug Zaleplon, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Bacteroides stercoris (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 8 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides stercoris co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clonidine |
Click to Show/Hide the Detail |
| Drug ID |
DR0352
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides stercoris co-metabolize the drug Clonidine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[23], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides stercoris co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Dexamethasone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR0451
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides stercoris co-metabolize the drug Dexamethasone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[25], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides stercoris co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides stercoris co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides stercoris co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides stercoris co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Bacteroides thetaiotaomicron (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 17 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clonidine |
Click to Show/Hide the Detail |
| Drug ID |
DR0352
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Clonidine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[23], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Dexamethasone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR0451
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Dexamethasone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[25], [1] |
| Diltiazem hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0509
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Diltiazem hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[21], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Irinotecan hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0881
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) metabolizes the drug Irinotecan hydrochloride, and Bacteroides thetaiotaomicron further metabolizes its metabolite (SN-38G), which can indirectly affect efficacy, safety or bioavailability of this drug. |
[33], [34] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Nateglinide |
Click to Show/Hide the Detail |
| Drug ID |
DR1132
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Nateglinide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paclitaxel |
Click to Show/Hide the Detail |
| Drug ID |
DR1227
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Paclitaxel, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Ritonavir |
Click to Show/Hide the Detail |
| Drug ID |
DR1430
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Ritonavir, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [9] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Tadalafil |
Click to Show/Hide the Detail |
| Drug ID |
DR1525
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides thetaiotaomicron co-metabolize the drug Tadalafil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[31], [1] |
| Bacteroides uniformis (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 7 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides uniformis co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides uniformis co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Irinotecan hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0881
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) metabolizes the drug Irinotecan hydrochloride, and Bacteroides uniformis further metabolizes its metabolite (SN-38G), which can indirectly affect efficacy, safety or bioavailability of this drug. |
[33], [34] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides uniformis co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides uniformis co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides uniformis co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides uniformis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Bacteroides vulgatus (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 17 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Finasteride |
Click to Show/Hide the Detail |
| Drug ID |
DR0695
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Finasteride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Imatinib mesylate |
Click to Show/Hide the Detail |
| Drug ID |
DR0858
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Imatinib mesylate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[35], [1] |
| Losartan potassium |
Click to Show/Hide the Detail |
| Drug ID |
DR0984
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Losartan potassium, which can collectively affect efficacy, safety or bioavailability of this drug. |
[11], [1] |
| Mifepristone |
Click to Show/Hide the Detail |
| Drug ID |
DR1091
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Mifepristone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[26], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Nateglinide |
Click to Show/Hide the Detail |
| Drug ID |
DR1132
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Nateglinide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Oxybutynin chloride |
Click to Show/Hide the Detail |
| Drug ID |
DR1219
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Oxybutynin chloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[12], [1] |
| Phenytoin |
Click to Show/Hide the Detail |
| Drug ID |
DR1282
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Phenytoin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[27], [1] |
| Ritonavir |
Click to Show/Hide the Detail |
| Drug ID |
DR1430
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Ritonavir, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Verapamil hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR1681
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Verapamil hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[36], [1] |
| Zaleplon |
Click to Show/Hide the Detail |
| Drug ID |
DR1725
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides vulgatus co-metabolize the drug Zaleplon, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Bacteroides xylanisolvens (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 18 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Dexamethasone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR0451
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Dexamethasone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[25], [1] |
| Diltiazem hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0509
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Diltiazem hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[21], [1] |
| Finasteride |
Click to Show/Hide the Detail |
| Drug ID |
DR0695
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Finasteride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Losartan potassium |
Click to Show/Hide the Detail |
| Drug ID |
DR0984
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Losartan potassium, which can collectively affect efficacy, safety or bioavailability of this drug. |
[11], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Nateglinide |
Click to Show/Hide the Detail |
| Drug ID |
DR1132
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Nateglinide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Oxybutynin chloride |
Click to Show/Hide the Detail |
| Drug ID |
DR1219
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Oxybutynin chloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[12], [1] |
| Paclitaxel |
Click to Show/Hide the Detail |
| Drug ID |
DR1227
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Paclitaxel, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Phenytoin |
Click to Show/Hide the Detail |
| Drug ID |
DR1282
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Phenytoin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[27], [1] |
| Ritonavir |
Click to Show/Hide the Detail |
| Drug ID |
DR1430
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Ritonavir, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Zaleplon |
Click to Show/Hide the Detail |
| Drug ID |
DR1725
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides xylanisolvens co-metabolize the drug Zaleplon, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Odoribacter splanchnicus (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 17 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clonidine |
Click to Show/Hide the Detail |
| Drug ID |
DR0352
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Clonidine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[23], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Finasteride |
Click to Show/Hide the Detail |
| Drug ID |
DR0695
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Finasteride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Losartan potassium |
Click to Show/Hide the Detail |
| Drug ID |
DR0984
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Losartan potassium, which can collectively affect efficacy, safety or bioavailability of this drug. |
[11], [1] |
| Mifepristone |
Click to Show/Hide the Detail |
| Drug ID |
DR1091
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Mifepristone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[26], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Nateglinide |
Click to Show/Hide the Detail |
| Drug ID |
DR1132
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Nateglinide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Oxybutynin chloride |
Click to Show/Hide the Detail |
| Drug ID |
DR1219
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Oxybutynin chloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[12], [1] |
| Paclitaxel |
Click to Show/Hide the Detail |
| Drug ID |
DR1227
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Paclitaxel, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Ritonavir |
Click to Show/Hide the Detail |
| Drug ID |
DR1430
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Ritonavir, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Odoribacter splanchnicus co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Parabacteroides distasonis (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 12 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides distasonis co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides distasonis co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Diltiazem hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0509
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides distasonis co-metabolize the drug Diltiazem hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[21], [1] |
| Finasteride |
Click to Show/Hide the Detail |
| Drug ID |
DR0695
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides distasonis co-metabolize the drug Finasteride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides distasonis co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Losartan potassium |
Click to Show/Hide the Detail |
| Drug ID |
DR0984
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides distasonis co-metabolize the drug Losartan potassium, which can collectively affect efficacy, safety or bioavailability of this drug. |
[11], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides distasonis co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Nateglinide |
Click to Show/Hide the Detail |
| Drug ID |
DR1132
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides distasonis co-metabolize the drug Nateglinide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Phenytoin |
Click to Show/Hide the Detail |
| Drug ID |
DR1282
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides distasonis co-metabolize the drug Phenytoin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[27], [1] |
| Ritonavir |
Click to Show/Hide the Detail |
| Drug ID |
DR1430
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides distasonis co-metabolize the drug Ritonavir, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides distasonis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides distasonis co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Parabacteroides johnsonii (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 8 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides johnsonii co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides johnsonii co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Diltiazem hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0509
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides johnsonii co-metabolize the drug Diltiazem hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[21], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides johnsonii co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Losartan potassium |
Click to Show/Hide the Detail |
| Drug ID |
DR0984
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides johnsonii co-metabolize the drug Losartan potassium, which can collectively affect efficacy, safety or bioavailability of this drug. |
[11], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides johnsonii co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides johnsonii co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides johnsonii co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Parabacteroides merdae (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 10 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides merdae co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides merdae co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides merdae co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Losartan potassium |
Click to Show/Hide the Detail |
| Drug ID |
DR0984
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides merdae co-metabolize the drug Losartan potassium, which can collectively affect efficacy, safety or bioavailability of this drug. |
[11], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides merdae co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Nateglinide |
Click to Show/Hide the Detail |
| Drug ID |
DR1132
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides merdae co-metabolize the drug Nateglinide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides merdae co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides merdae co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides merdae co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Parabacteroides merdae co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Prevotella copri (CFB bacteria) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Prevotella copri co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Prevotella copri co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Prevotella copri co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Prevotella copri co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Prevotella copri co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Prevotella copri co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Bacteria: Firmicutes |
|---|
| Anaerobutyricum hallii (firmicutes) |
Click to Show/Hide the Full List of Drugs: 7 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerobutyricum hallii co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerobutyricum hallii co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerobutyricum hallii co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerobutyricum hallii co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerobutyricum hallii co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerobutyricum hallii co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerobutyricum hallii co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Anaerococcus hydrogenalis (firmicutes) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerococcus hydrogenalis co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerococcus hydrogenalis co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerococcus hydrogenalis co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerococcus hydrogenalis co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerococcus hydrogenalis co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerococcus hydrogenalis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Anaerostipes hadrus (firmicutes) |
Click to Show/Hide the Full List of Drugs: 5 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerostipes hadrus co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Imatinib mesylate |
Click to Show/Hide the Detail |
| Drug ID |
DR0858
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerostipes hadrus co-metabolize the drug Imatinib mesylate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[35], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerostipes hadrus co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerostipes hadrus co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerostipes hadrus co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Anaerotruncus colihominis (firmicutes) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerotruncus colihominis co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerotruncus colihominis co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerotruncus colihominis co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Pimozide |
Click to Show/Hide the Detail |
| Drug ID |
DR1291
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerotruncus colihominis co-metabolize the drug Pimozide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerotruncus colihominis co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Anaerotruncus colihominis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Bacillus megaterium (firmicutes) |
Click to Show/Hide the Full List of Drugs: 7 Drugs Metabolized
|
| Acetaminophen |
Click to Show/Hide the Detail |
| Drug ID |
DR0037
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacillus megaterium co-metabolize the drug Acetaminophen, which can collectively affect efficacy, safety or bioavailability of this drug. |
[37], [38] |
| Buspirone |
Click to Show/Hide the Detail |
| Drug ID |
DR0248
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacillus megaterium co-metabolize the drug Buspirone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[39], [38], [40] |
| Dextromethorphan hydrobromide |
Click to Show/Hide the Detail |
| Drug ID |
DR0476
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacillus megaterium co-metabolize the drug Dextromethorphan hydrobromide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[11], [38] |
| Nifedipine |
Click to Show/Hide the Detail |
| Drug ID |
DR1152
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacillus megaterium co-metabolize the drug Nifedipine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[16], [41], [38] |
| Progesterone |
Click to Show/Hide the Detail |
| Drug ID |
DR1346
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacillus megaterium co-metabolize the drug Progesterone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[42], [40] |
| Propranolol hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR1367
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacillus megaterium co-metabolize the drug Propranolol hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[43], [40] |
| Testosterone cypionate |
Click to Show/Hide the Detail |
| Drug ID |
DR1564
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacillus megaterium co-metabolize the drug Testosterone cypionate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[16], [40], [44] |
| Bacteroides pectinophilus (firmicutes) |
Click to Show/Hide the Full List of Drugs: 3 Drugs Metabolized
|
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides pectinophilus co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides pectinophilus co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Bacteroides pectinophilus co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Blautia hansenii (firmicutes) |
Click to Show/Hide the Full List of Drugs: 19 Drugs Metabolized
|
| Anastrozole |
Click to Show/Hide the Detail |
| Drug ID |
DR0113
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Anastrozole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[45], [1] |
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Dasatinib |
Click to Show/Hide the Detail |
| Drug ID |
DR0423
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Dasatinib, which can collectively affect efficacy, safety or bioavailability of this drug. |
[10], [1] |
| Diltiazem hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0509
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Diltiazem hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[21], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mifepristone |
Click to Show/Hide the Detail |
| Drug ID |
DR1091
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Mifepristone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[26], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Nateglinide |
Click to Show/Hide the Detail |
| Drug ID |
DR1132
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Nateglinide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Nevirapine |
Click to Show/Hide the Detail |
| Drug ID |
DR1142
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Nevirapine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[46], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Oxybutynin chloride |
Click to Show/Hide the Detail |
| Drug ID |
DR1219
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Oxybutynin chloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[12], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Ritonavir |
Click to Show/Hide the Detail |
| Drug ID |
DR1430
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Ritonavir, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sildenafil citrate |
Click to Show/Hide the Detail |
| Drug ID |
DR1481
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Sildenafil citrate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[47], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Zaleplon |
Click to Show/Hide the Detail |
| Drug ID |
DR1725
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia hansenii co-metabolize the drug Zaleplon, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Blautia luti (firmicutes) |
Click to Show/Hide the Full List of Drugs: 7 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia luti co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia luti co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia luti co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia luti co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia luti co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia luti co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Blautia luti co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Clostridioides difficile (firmicutes) |
Click to Show/Hide the Full List of Drugs: 9 Drugs Metabolized
|
| Acetaminophen |
Click to Show/Hide the Detail |
| Drug ID |
DR0037
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridioides difficile co-metabolize the drug Acetaminophen, which can collectively affect efficacy, safety or bioavailability of this drug. |
[37], [48] |
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridioides difficile co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridioides difficile co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridioides difficile co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridioides difficile co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridioides difficile co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sildenafil citrate |
Click to Show/Hide the Detail |
| Drug ID |
DR1481
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridioides difficile co-metabolize the drug Sildenafil citrate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[47], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridioides difficile co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridioides difficile co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Clostridium botulinum (firmicutes) |
Click to Show/Hide the Full List of Drugs: 20 Drugs Metabolized
|
| Anastrozole |
Click to Show/Hide the Detail |
| Drug ID |
DR0113
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Anastrozole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[45], [1] |
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Dasatinib |
Click to Show/Hide the Detail |
| Drug ID |
DR0423
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Dasatinib, which can collectively affect efficacy, safety or bioavailability of this drug. |
[10], [1] |
| Diltiazem hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0509
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Diltiazem hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[21], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mifepristone |
Click to Show/Hide the Detail |
| Drug ID |
DR1091
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Mifepristone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[26], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Nateglinide |
Click to Show/Hide the Detail |
| Drug ID |
DR1132
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Nateglinide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Nevirapine |
Click to Show/Hide the Detail |
| Drug ID |
DR1142
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Nevirapine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[46], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Oxybutynin chloride |
Click to Show/Hide the Detail |
| Drug ID |
DR1219
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Oxybutynin chloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[12], [1] |
| Pimozide |
Click to Show/Hide the Detail |
| Drug ID |
DR1291
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Pimozide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Ritonavir |
Click to Show/Hide the Detail |
| Drug ID |
DR1430
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Ritonavir, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sildenafil citrate |
Click to Show/Hide the Detail |
| Drug ID |
DR1481
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Sildenafil citrate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[47], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Zaleplon |
Click to Show/Hide the Detail |
| Drug ID |
DR1725
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium botulinum co-metabolize the drug Zaleplon, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clostridium leptum (firmicutes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| RO-7-0207 |
Click to Show/Hide the Detail |
| Drug ID |
DR1204
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium leptum co-metabolize the drug RO-7-0207, which can collectively affect efficacy, safety or bioavailability of this drug. |
[49], [50] |
| Clostridium perfringens (firmicutes) |
Click to Show/Hide the Full List of Drugs: 5 Drugs Metabolized
|
| Irinotecan hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0881
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) metabolizes the drug Irinotecan hydrochloride, and Clostridium perfringens further metabolizes its metabolite (SN-38G), which can indirectly affect efficacy, safety or bioavailability of this drug. |
[33], [51] |
| Metronidazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1073
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium perfringens co-metabolize the drug Metronidazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[28], [52] |
| Metronidazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1073
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium perfringens co-metabolize the drug Metronidazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[28], [52] |
| RO-7-0207 |
Click to Show/Hide the Detail |
| Drug ID |
DR1204
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium perfringens co-metabolize the drug RO-7-0207, which can collectively affect efficacy, safety or bioavailability of this drug. |
[49], [50] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium perfringens co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [6], [7] |
| Clostridium scindens (firmicutes) |
Click to Show/Hide the Full List of Drugs: 7 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium scindens co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Dexamethasone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR0451
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium scindens co-metabolize the drug Dexamethasone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[25], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium scindens co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium scindens co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium scindens co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium scindens co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium scindens co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Clostridium spiroforme (firmicutes) |
Click to Show/Hide the Full List of Drugs: 4 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium spiroforme co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium spiroforme co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium spiroforme co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium spiroforme co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Clostridium sporogenes (firmicutes) |
Click to Show/Hide the Full List of Drugs: 10 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium sporogenes co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Clopidogrel bisulfate |
Click to Show/Hide the Detail |
| Drug ID |
DR0355
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium sporogenes co-metabolize the drug Clopidogrel bisulfate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[24], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium sporogenes co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium sporogenes co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium sporogenes co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium sporogenes co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| RO-7-0207 |
Click to Show/Hide the Detail |
| Drug ID |
DR1204
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium sporogenes co-metabolize the drug RO-7-0207, which can collectively affect efficacy, safety or bioavailability of this drug. |
[49], [50] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium sporogenes co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium sporogenes co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Zonisamide |
Click to Show/Hide the Detail |
| Drug ID |
DR1737
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium sporogenes co-metabolize the drug Zonisamide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[53], [54] |
| Clostridium symbiosum (firmicutes) |
Click to Show/Hide the Full List of Drugs: 5 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium symbiosum co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium symbiosum co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium symbiosum co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium symbiosum co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Clostridium symbiosum co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Coprococcus comes (firmicutes) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Coprococcus comes co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Coprococcus comes co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Coprococcus comes co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Coprococcus comes co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Coprococcus comes co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Coprococcus comes co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Dorea formicigenerans (firmicutes) |
Click to Show/Hide the Full List of Drugs: 5 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Dorea formicigenerans co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Dorea formicigenerans co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Dorea formicigenerans co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Dorea formicigenerans co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Dorea formicigenerans co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Enterocloster asparagiformis (firmicutes) |
Click to Show/Hide the Full List of Drugs: 7 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster asparagiformis co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster asparagiformis co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster asparagiformis co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster asparagiformis co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster asparagiformis co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster asparagiformis co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster asparagiformis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Enterocloster bolteae (firmicutes) |
Click to Show/Hide the Full List of Drugs: 8 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster bolteae co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Dasatinib |
Click to Show/Hide the Detail |
| Drug ID |
DR0423
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster bolteae co-metabolize the drug Dasatinib, which can collectively affect efficacy, safety or bioavailability of this drug. |
[10], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster bolteae co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster bolteae co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster bolteae co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Pimozide |
Click to Show/Hide the Detail |
| Drug ID |
DR1291
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster bolteae co-metabolize the drug Pimozide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster bolteae co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterocloster bolteae co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Enterococcus casseliflavus (firmicutes) |
Click to Show/Hide the Full List of Drugs: 2 Drugs Metabolized
|
| Metronidazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1073
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterococcus casseliflavus co-metabolize the drug Metronidazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[28], [55] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterococcus casseliflavus co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [9] |
| Enterococcus faecalis (firmicutes) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| Acetaminophen |
Click to Show/Hide the Detail |
| Drug ID |
DR0037
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterococcus faecalis co-metabolize the drug Acetaminophen, which can collectively affect efficacy, safety or bioavailability of this drug. |
[37], [48] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterococcus faecalis co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterococcus faecalis co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterococcus faecalis co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterococcus faecalis co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterococcus faecalis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Enterococcus faecium (firmicutes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterococcus faecium co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [6], [7] |
| Enterococcus gallinarum (firmicutes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Metronidazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1073
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterococcus gallinarum co-metabolize the drug Metronidazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[28], [55] |
| Erysipelatoclostridium ramosum (firmicutes) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Erysipelatoclostridium ramosum co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Erysipelatoclostridium ramosum co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Erysipelatoclostridium ramosum co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Erysipelatoclostridium ramosum co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Erysipelatoclostridium ramosum co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Erysipelatoclostridium ramosum co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Eubacterium cellulosolvens (firmicutes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| BRN-0077922 |
Click to Show/Hide the Detail |
| Drug ID |
DR0786
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eubacterium cellulosolvens co-metabolize the drug BRN-0077922, which can collectively affect efficacy, safety or bioavailability of this drug. |
[56], [57] |
| Eubacterium oxidoreducens (firmicutes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| RO-7-0207 |
Click to Show/Hide the Detail |
| Drug ID |
DR1204
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eubacterium oxidoreducens co-metabolize the drug RO-7-0207, which can collectively affect efficacy, safety or bioavailability of this drug. |
[49], [50] |
| Eubacterium rectale (firmicutes) |
Click to Show/Hide the Full List of Drugs: 7 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eubacterium rectale co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eubacterium rectale co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eubacterium rectale co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eubacterium rectale co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eubacterium rectale co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eubacterium rectale co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eubacterium rectale co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Eubacterium ventriosum (firmicutes) |
Click to Show/Hide the Full List of Drugs: 3 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eubacterium ventriosum co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eubacterium ventriosum co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Eubacterium ventriosum co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Holdemanella biformis (firmicutes) |
Click to Show/Hide the Full List of Drugs: 9 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Holdemanella biformis co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Holdemanella biformis co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Holdemanella biformis co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Holdemanella biformis co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Holdemanella biformis co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Oxybutynin chloride |
Click to Show/Hide the Detail |
| Drug ID |
DR1219
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Holdemanella biformis co-metabolize the drug Oxybutynin chloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[12], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Holdemanella biformis co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Holdemanella biformis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Holdemanella biformis co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Hungatella hathewayi (firmicutes) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Hungatella hathewayi co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Hungatella hathewayi co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Hungatella hathewayi co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Hungatella hathewayi co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Hungatella hathewayi co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Hungatella hathewayi co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Lactobacillus acidophilus (firmicutes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Lactobacillus acidophilus co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [6], [7] |
| Lactobacillus buchneri (firmicutes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Lactobacillus buchneri co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [9] |
| Lactobacillus johnsonii (firmicutes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Tegafur |
Click to Show/Hide the Detail |
| Drug ID |
DR1539
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Lactobacillus johnsonii co-metabolize the drug Tegafur, which can collectively affect efficacy, safety or bioavailability of this drug. |
[58], [59] |
| Lactobacillus reuteri (firmicutes) |
Click to Show/Hide the Full List of Drugs: 5 Drugs Metabolized
|
| Dasatinib |
Click to Show/Hide the Detail |
| Drug ID |
DR0423
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Lactobacillus reuteri co-metabolize the drug Dasatinib, which can collectively affect efficacy, safety or bioavailability of this drug. |
[10], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Lactobacillus reuteri co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Lactobacillus reuteri co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Lactobacillus reuteri co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Lactobacillus reuteri co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Lactobacillus sakei (firmicutes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Erythromycin stearate |
Click to Show/Hide the Detail |
| Drug ID |
DR0614
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Lactobacillus sakei co-metabolize the drug Erythromycin stearate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[60], [61], [62] |
| Marvinbryantia formatexigens (firmicutes) |
Click to Show/Hide the Full List of Drugs: 4 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Marvinbryantia formatexigens co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Marvinbryantia formatexigens co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Marvinbryantia formatexigens co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Marvinbryantia formatexigens co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Mediterraneibacter glycyrrhizinilyticus (firmicutes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| BRN-0077922 |
Click to Show/Hide the Detail |
| Drug ID |
DR0786
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Mediterraneibacter glycyrrhizinilyticus co-metabolize the drug BRN-0077922, which can collectively affect efficacy, safety or bioavailability of this drug. |
[56], [63] |
| Roseburia intestinalis (firmicutes) |
Click to Show/Hide the Full List of Drugs: 8 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Roseburia intestinalis co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Roseburia intestinalis co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Roseburia intestinalis co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Roseburia intestinalis co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Roseburia intestinalis co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Roseburia intestinalis co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Roseburia intestinalis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Roseburia intestinalis co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Ruminococcus gnavus (firmicutes) |
Click to Show/Hide the Full List of Drugs: 7 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus gnavus co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus gnavus co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus gnavus co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus gnavus co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus gnavus co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus gnavus co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus gnavus co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Ruminococcus lactaris (firmicutes) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus lactaris co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus lactaris co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus lactaris co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus lactaris co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus lactaris co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus lactaris co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Ruminococcus torques (firmicutes) |
Click to Show/Hide the Full List of Drugs: 5 Drugs Metabolized
|
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus torques co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus torques co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus torques co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus torques co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Ruminococcus torques co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Streptococcus agalactiae (firmicutes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Irinotecan hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0881
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) metabolizes the drug Irinotecan hydrochloride, and Streptococcus agalactiae further metabolizes its metabolite (SN-38G), which can indirectly affect efficacy, safety or bioavailability of this drug. |
[33], [51] |
| Streptococcus salivarius (firmicutes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Streptococcus salivarius co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [6] |
| Subdoligranulum variabile (firmicutes) |
Click to Show/Hide the Full List of Drugs: 7 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Subdoligranulum variabile co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Subdoligranulum variabile co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Subdoligranulum variabile co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Subdoligranulum variabile co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Subdoligranulum variabile co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Subdoligranulum variabile co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Subdoligranulum variabile co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Bacteria: Lentisphaerae |
|---|
| Victivallis vadensis (PVC bacteria) |
Click to Show/Hide the Full List of Drugs: 6 Drugs Metabolized
|
| BRN-0498823 |
Click to Show/Hide the Detail |
| Drug ID |
DR1167
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Victivallis vadensis co-metabolize the drug BRN-0498823, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Diltiazem hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0509
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Victivallis vadensis co-metabolize the drug Diltiazem hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[21], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Victivallis vadensis co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Victivallis vadensis co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Victivallis vadensis co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Victivallis vadensis co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Bacteria: Proteobacteria |
|---|
| Citrobacter freundii (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Acetaminophen |
Click to Show/Hide the Detail |
| Drug ID |
DR0037
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Citrobacter freundii co-metabolize the drug Acetaminophen, which can collectively affect efficacy, safety or bioavailability of this drug. |
[37], [48] |
| Edwardsiella tarda (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 2 Drugs Metabolized
|
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Edwardsiella tarda co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Edwardsiella tarda co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Enterobacter cancerogenus (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 5 Drugs Metabolized
|
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterobacter cancerogenus co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterobacter cancerogenus co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterobacter cancerogenus co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paliperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1230
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterobacter cancerogenus co-metabolize the drug Paliperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Risperidone |
Click to Show/Hide the Detail |
| Drug ID |
DR1428
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterobacter cancerogenus co-metabolize the drug Risperidone, which can collectively affect efficacy, safety or bioavailability of this drug. |
[8], [1] |
| Enterobacter cloacae (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Metronidazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1073
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Enterobacter cloacae co-metabolize the drug Metronidazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[28], [64] |
| Escherichia coli (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 12 Drugs Metabolized
|
| Acetaminophen |
Click to Show/Hide the Detail |
| Drug ID |
DR0037
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Escherichia coli co-metabolize the drug Acetaminophen, which can collectively affect efficacy, safety or bioavailability of this drug. |
[37], [48] |
| Doxorubicin |
Click to Show/Hide the Detail |
| Drug ID |
DR0546
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Escherichia coli co-metabolize the drug Doxorubicin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[19], [65] |
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Escherichia coli co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Irinotecan hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0881
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) metabolizes the drug Irinotecan hydrochloride, and Escherichia coli further metabolizes its metabolite (SN-38G), which can indirectly affect efficacy, safety or bioavailability of this drug. |
[33], [66] |
| Irinotecan hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0881
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Escherichia coli co-metabolize the drug Irinotecan hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[33], [66] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Escherichia coli co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Norethindrone acetate |
Click to Show/Hide the Detail |
| Drug ID |
DR1750
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Escherichia coli co-metabolize the drug Norethindrone acetate, which can collectively affect efficacy, safety or bioavailability of this drug. |
[22], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Escherichia coli co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Paclitaxel |
Click to Show/Hide the Detail |
| Drug ID |
DR1227
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Escherichia coli co-metabolize the drug Paclitaxel, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Ritonavir |
Click to Show/Hide the Detail |
| Drug ID |
DR1430
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Escherichia coli co-metabolize the drug Ritonavir, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Escherichia coli co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Escherichia coli co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Klebsiella pneumoniae (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 2 Drugs Metabolized
|
| Aztreonam |
Click to Show/Hide the Detail |
| Drug ID |
DR0169
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Klebsiella pneumoniae co-metabolize the drug Aztreonam, which can collectively affect efficacy, safety or bioavailability of this drug. |
[67], [68] |
| Doxorubicin |
Click to Show/Hide the Detail |
| Drug ID |
DR0546
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Klebsiella pneumoniae co-metabolize the drug Doxorubicin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[19], [65] |
| Klebsiella variicola (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Aztreonam |
Click to Show/Hide the Detail |
| Drug ID |
DR0169
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Klebsiella variicola co-metabolize the drug Aztreonam, which can collectively affect efficacy, safety or bioavailability of this drug. |
[67], [69] |
| Proteus penneri (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 4 Drugs Metabolized
|
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Proteus penneri co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Proteus penneri co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Proteus penneri co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Sulfasalazine |
Click to Show/Hide the Detail |
| Drug ID |
DR1513
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Proteus penneri co-metabolize the drug Sulfasalazine, which can collectively affect efficacy, safety or bioavailability of this drug. |
[5], [1] |
| Providencia alcalifaciens (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 3 Drugs Metabolized
|
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Providencia alcalifaciens co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Providencia alcalifaciens co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Providencia alcalifaciens co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Providencia rettgeri (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 2 Drugs Metabolized
|
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Providencia rettgeri co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Providencia rettgeri co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Providencia stuartii (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 3 Drugs Metabolized
|
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Providencia stuartii co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Providencia stuartii co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Providencia stuartii co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Raoultella planticola (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Doxorubicin |
Click to Show/Hide the Detail |
| Drug ID |
DR0546
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Raoultella planticola co-metabolize the drug Doxorubicin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[19], [65] |
| Salmonella enterica (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 4 Drugs Metabolized
|
| Fluoxetine hydrochloride |
Click to Show/Hide the Detail |
| Drug ID |
DR0720
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Salmonella enterica co-metabolize the drug Fluoxetine hydrochloride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[2], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Salmonella enterica co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Salmonella enterica co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| RO-7-0207 |
Click to Show/Hide the Detail |
| Drug ID |
DR1204
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Salmonella enterica co-metabolize the drug RO-7-0207, which can collectively affect efficacy, safety or bioavailability of this drug. |
[49], [70] |
| Bacteria: Verrucomicrobia |
|---|
| Akkermansia muciniphila (verrucomicrobiae) |
Click to Show/Hide the Full List of Drugs: 5 Drugs Metabolized
|
| Finasteride |
Click to Show/Hide the Detail |
| Drug ID |
DR0695
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Akkermansia muciniphila co-metabolize the drug Finasteride, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Mycophenolate mofetil |
Click to Show/Hide the Detail |
| Drug ID |
DR1118
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Akkermansia muciniphila co-metabolize the drug Mycophenolate mofetil, which can collectively affect efficacy, safety or bioavailability of this drug. |
[3], [1] |
| Omeprazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1196
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Akkermansia muciniphila co-metabolize the drug Omeprazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [1] |
| Pimozide |
Click to Show/Hide the Detail |
| Drug ID |
DR1291
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Akkermansia muciniphila co-metabolize the drug Pimozide, which can collectively affect efficacy, safety or bioavailability of this drug. |
[], [1] |
| Tacrolimus |
Click to Show/Hide the Detail |
| Drug ID |
DR1524
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Akkermansia muciniphila co-metabolize the drug Tacrolimus, which can collectively affect efficacy, safety or bioavailability of this drug. |
[13], [1] |
| Fungi: Ascomycota |
|---|
| Saccharomyces cerevisiae (ascomycota) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Acetaminophen |
Click to Show/Hide the Detail |
| Drug ID |
DR0037
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) metabolizes the drug Acetaminophen, and Saccharomyces cerevisiae further metabolizes its metabolite (1-Phenyl-1,2-propanedione), which can indirectly affect efficacy, safety or bioavailability of this drug. |
[37], [48] |
| Amoebozoa: Evosea |
|---|
| Entamoeba histolytica (eukaryotes) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Metronidazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1073
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Entamoeba histolytica co-metabolize the drug Metronidazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[28], [71] |
| Metamonada: Fornicata |
|---|
| Giardia intestinalis (diplomonads) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Metronidazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1073
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Giardia intestinalis co-metabolize the drug Metronidazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[28], [71] |
| Metamonada: Parabasalia |
|---|
| Trichomonas vaginalis (trichomonads) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Metronidazole |
Click to Show/Hide the Detail |
| Drug ID |
DR1073
Drug Info
|
| Interaction Mechanism |
Human Cytochrome P450 3A5 (CYP3A5) and Trichomonas vaginalis co-metabolize the drug Metronidazole, which can collectively affect efficacy, safety or bioavailability of this drug. |
[28], [71] |
|
|
|
|
|
|
